Deal drives IND advances
A collaboration between London-based Pharmaterials and Penn Pharmaceutical Services in South Wales will enable virtual, small and medium-sized pharmaceutical companies to progress investigational medicinal products (IMPs) through to clinical trials manufacture, using a wide variety of materials characterisation, pre-formulation and formulation techniques.
Clients will be able to combine state-of-the art analytical techniques for materials characterisation and product development offered by Pharmaterials with Penn's larger scale, GMP compliant, formulation development, clinical manufacturing and stability monitoring functions.
Dr Chris Higgins, Penn's director of business development, said: 'Penn has a strong track-record in conducting formulation development projects to GMP standards for virtual, small and medium-sized pharmaceutical companies. Through our partnership with Pharmaterials we can now add specialist services for solid-form r&d and pre-formulation screening, thereby operating a seamless process from project concept to contract manufacture.